Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands
Patent 5714142 Issued on February 3, 1998. Estimated Expiration Date: 
June 13, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 13, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesCyclodextrins as carriers Conjugates of monophenyl thyroid analogs useful in assays Patent #: 5273885 InventorsApplicationNo. 664372 filed on 06/13/1996US Classes:424/85.2, Interleukin424/85.4, Interferon514/11, Monocyclic514/16, 7 or 8 peptide repeating units in known peptide chain514/263.22, The additional hetero ring is six-membered consisting of one nitrogen and five carbons514/263.24, The additional chalcogen containing hetero ring is part of a polycyclo ring system514/263.3, Chalcogen bonded directly to a ring carbon of the purine ring system514/274, Chalcogen bonded directly to pyrimidine at 2-position514/335, Chalcogen bonded directly to a ring carbon of the six-membered hetero ring514/368, Ring nitrogen is shared by the cyclos of the bicyclo ring system (e.g., tetramisole, etc.)514/421, Chalcogen bonded directly to ring carbon of the five-membered hetero ring (e.g., adrenochrome, etc.)514/423, C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen)514/460, Chalcogen bonded directly to ring carbon of the hetero ring514/471, Nitrogen containing514/567, Benzene ring nonionically bonded514/568, Benzene ring nonionically bonded514/571, Ether oxygen single bonded to carboxylic acid, percarboxylic acid or salt thereof through an acyclic carbon or acyclic carbon chain514/620, The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding514/626, Nitrogen in R514/737, Nuclear halogenated514/772, DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING OTHER THAN HYDROCARBON514/776Albumin or derivativeExaminersPrimary: Clardy, S. MarkAttorney, Agent or FirmForeign Patent References
International ClassA61K 047/48AbstractCompositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.Other References
Field of SearchInterleukinInterferon Albumin or derivative DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING OTHER THAN HYDROCARBON Monocyclic 7 or 8 peptide repeating units in known peptide chain Chalcogen bonded directly to pyrimidine at 2-position Chalcogen bonded directly to a ring carbon of the six-membered hetero ring Ring nitrogen is shared by the cyclos of the bicyclo ring system (e.g., tetramisole, etc.) Chalcogen bonded directly to ring carbon of the five-membered hetero ring (e.g., adrenochrome, etc.) C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen) Chalcogen bonded directly to ring carbon of the hetero ring Nitrogen containing Benzene ring nonionically bonded Benzene ring nonionically bonded Ether oxygen single bonded to carboxylic acid, percarboxylic acid or salt thereof through an acyclic carbon or acyclic carbon chain The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding Nitrogen in R Nuclear halogenated | |
